Bovi-Shield® GOLD 5
Pfizer
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine
Modified Live Virus
Product Description:
Bovi-Shield Gold 5 is for vaccination of healthy cattle as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus; bovine viral diarrhea (Types 1 and 2) caused by bovine viral diarrhea (BVD) virus; and disease caused by parainfluenza3 (PI3) virus and bovine respiratory syncytial virus (BRSV). Bovi-Shield Gold 5 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with Bovi-Shield FP 4+L5, Bovi-Shield FP 4+VL5, Bovi-Shield Gold FP 5 L5, Bovi-Shield Gold FP 5 VL5, PregGuard FP 9 or PregGuard Gold FP 10 within the past 12 months. Bovi-Shield Gold 5 may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above. Bovi-Shield Gold 5 is a freeze-dried preparation of modified live virus (MLV) strains of IBR, BVD (Types 1 and 2), PI3, and BRSV viruses, plus a sterile diluent used to rehydrate the freeze-dried vaccine. Viral antigens are propagated on established cell lines.
Disease Description:
IBR, BVD, PI3, and BRSV viruses are commonly associated with respiratory disease and/or reproductive failure in cattle. IBR virus infection is characterized by high temperature, excessive nasal discharge, conjunctivitis and ocular discharge, inflamed nose (“red nose”), increased rate of respiration, coughing, loss of appetite, and depression. Cattle infected during pregnancy may abort.
BVD virus may be transmitted in nasal secretions, saliva, blood, feces and/or urine, and by direct contact with contaminated objects; it invades through the nose and mouth and replicates systemically. Infection during pregnancy may result in abortion, fetal resorption, or congenital malformation of the fetus. Moreover, if susceptible cows are infected with noncytopathic BVD virus during the first trimester of pregnancy, their calves may be born persistently infected with the virus. Exposure of those calves to certain virulent cytopathic BVD virus strains may precipitate BVD-mucosal disease. Both BVD Types 1 and 2 can show a variety of clinical signs. The signs may be mild and not readily apparent. Clinical signs may include severe immune suppression, diarrhea, anorexia, depression, fever and respiratory disease. If infected with some Type 2 strains of BVD, severe thrombocytopenia may occur and hemorrhaging may be seen.
PI3 virus usually localizes in the upper respiratory tract, causing elevated temperature and moderate nasal and ocular discharge. Although clinical signs typically are mild, PI3 infection weakens respiratory tissues. Invasion and replication of other pathogens, particularly Pasteurella spp., is therefore facilitated and may result in pneumonia.
BRSV is the etiologic agent of a specific viral respiratory disease of cattle of all ages, including nursing calves. Infection is characterized by rapid breathing, coughing, loss of appetite, discharge from the nose and eyes, fever, and swelling around the throat and neck. In an acute outbreak, deaths may follow within 48 hours after onset of signs. Clinically, BRSV infection may be indistinguishable from other viral infections associated with the bovine respiratory disease complex. BRSV infection, like PI3, facilitates invasion and replication of other respiratory pathogens. Exacerbation of clinical signs has been documented when concurrent BRSV and BVD or IBR infection exists.
Directions:
1. General Directions: Vaccination of healthy cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.
2. Primary Vaccination: Administer a single 2 mL dose to healthy cattle, followed by a second dose of Bovi-Shield BRSV 3-4 weeks later.
3. Revaccination: Annual revaccination with a single dose is recommended.
4. Good animal husbandry and herd health management practices should be employed.
Precautions:
1. Do not use in pregnant cows (abortions can result) unless they were vaccinated, with Bovi-Shield FP 4+L5, Bovi-Shield FP 4+VL5, Bovi-Shield Gold FP 5 L5, Bovi-Shield Gold FP 5 VL5, PregGuard FP 9 or PregGuard Gold FP 10 within the past 12 months. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above. Do not vaccinate neonatal calves.
2. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
3. Use entire contents when first opened.
4. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
5. Burn containers and all unused contents.
6. Do not vaccinate within 21 days before slaughter.
7. Contains gentamicin as preservative.
8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
9. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
For veterinary use only
